Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Cytek Biosciences Q2 EPS $(0.04), Inline, Sales $45.602M Miss $46.479M Estimate

Author: Benzinga Newsdesk | August 06, 2025 04:11pm
Cytek Biosciences (NASDAQ:CTKB) reported quarterly losses of $(0.04) per share which met the analyst consensus estimate. This is a 50 percent increase over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $45.602 million which missed the analyst consensus estimate of $46.479 million by 1.89 percent. This is a 2.18 percent decrease over sales of $46.617 million the same period last year.

Posted In: CTKB


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist